Nurix Therapeutics, Inc. (NRIX) Tops Q1 EPS by 2c

Nurix Therapeutics, Inc. (NASDAQ: NRIX) reported Q1 EPS of ($0.76), $0.02 better than the analyst estimate of ($0.78). Revenue for the quarter came in at $16.58 million versus the consensus estimate of $17.08 million.

For earnings history and earnings-related data on Nurix Therapeutics, Inc. (NRIX) click here.

You May Also Be Interested In

• Citrini flags overheating concerns as leverage, chip rally weigh on KOSPI
• Bernstein SocGen Reiterates Outperform Rating on Fervo Energy (FRVO)
• UBS Reiterates Buy Rating on General Motors (GM) as Defense Opportunity in Focus